Navigation Links
AccuVein and GSABC Enter into Purchasing Agreement for Vein Illumination Device
Date:6/8/2009

GSABC to Offer Members AccuVein's AV300 to Help Ease Venipuncture Process

UnitedPharma Named Preferred Blood Center Distributor for AccuVein AV300

COLD SPRING HARBOR, N.Y., June 8 /PRNewswire/ -- AccuVein LLC today announced a three-year agreement with Group Services for America's Blood Centers (GSABC) bringing the AccuVein AV300, the world's first hand-held, non-contact vein illumination device, to GSABC member blood centers. Under the agreement, GSABC will provide participating blood centers access to the AV300 to help locate hard-to-find veins. The AccuVein AV300 projects a pattern of light on a patient's skin revealing vein position to help the healthcare professional locate veins for blood draw (venipuncture).

"Providing the members of GSABC with the AccuVein AV300 is a big step towards reaching our goal -- providing all health professionals with a device that may reduce time and effort in establishing an IV line," said Stephen P. Conlon, President, AccuVein.

"GSABC is committed to providing our members access to the latest technology -- enhancing their Centers and providing their donors with top-of-the-line service," said Jerome Haarmann, President, GSABC. The device will be supplied by UnitedPharma, AccuVein's preferred distributor to Blood Centers.

About AccuVein

AccuVein applies advanced technologies to important healthcare challenges. Their innovative AV300 allows practitioners to see a map on the patient's skin of the position of veins, helping caregivers locate veins while they perform the most common invasive medical procedure -- venipuncture. Built using AccuVein's expertise in medical device miniaturization and user-intuitive design, the AV300 is the world's first portable, non-contact vein illumination solution. With more than a dozen patents filed worldwide, AccuVein demonstrates an ongoing commitment to invest in improving patient car
'/>"/>

SOURCE AccuVein
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AccuVein Inks National Three-Year Group Purchasing Deal With Amerinet
2. China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million
3. Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
4. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
5. Visage Imaging to Provide Visage(R) CS Enterprise Wide Advanced Visualization Solutions to Advanced Radiology Consultants
6. PDI and The Medical Affairs Company Enter Exclusive Strategic Alliance
7. UCB and Crohns Disease Working Group Award $175,000 in Research Grants to Gastroenterology Fellows
8. Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
9. Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing
10. Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor
11. CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...erman . , Whether it,s CD packaging, contain...uency Identification) are increasingly finding the...o label objects or goods and identify them automat... can read and process the data contained in the la...oduction conditions of up to 100 degrees Celsius. ...
(Date:11/24/2009)...Newswire/--Twomoreprestigiousuniversitieshavejoine...ndcareerssiteforlifescienceprofessionals. ,, No...obboard,joining28othermajorlifesciencetrainingInst...om ,isonlyforpost-graduatesinthelifesciences.While...net,BioCareerCenteristheonlyonethatserveslifescien...
(Date:11/24/2009)...care employment grew by 29,000 jobs in October, a...nt growth during the U.S. recession. However, clin... health systems are coming closer to having to act...istrators. , (Vocus) Nove...growing in October despite the shedding of jobs in...
(Date:11/24/2009)...-Asia/--ShanghaiBiolaxyannouncedthe,ChineseStateFo...stigationalnewdrugapplication(IND)foritsoralinsuli...treatdiabetes.ThisIND,approvalallowsBiolaxytoiniti...disordercharacteristicofhighbloodglucoseandpoor,me...veremicro-and,macro-vasculardiseases,lossofvision,...
Breaking Biology Technology:Intelligence inside metal components 2Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2
...0,000 planning grant from the Ewing Marion Kauffm...prehensive plan for cross-campus entrepreneurship ...W-Madison, along with 14 other U.S. universities, ...her awards of up to $5 million in the Collegiate E... and School of Business Dean Michael Knetter initi...
...s of poor service from Wisconsin customers two yea...Paul La Schiazza, president of SBC,s Wisconsin div... to be assured that SBC was not a small local comp...with the top-tier telecom companies. Last December...ech of Wisconsin would simply be called SBC, thus ...
...erge eFilm to offer an integrated PAC (picture ach...rmation system) solution to its target market of h... of RIS Logic is an important strategic milestone ...ices company focused on delivering comprehensive R... Linden, Merge eFilm president and CEO. Customers ...
Other Biology Technology:UW-Madison Receives Grant to Develop Entrepreneurship Proposal 2SBC is Here to Stay 2Merge eFilm to buy Ohio firm in $14M Deal 2Merge eFilm to buy Ohio firm in $14M Deal 3
(Date:11/24/2009)..., This release is available in Spanish . ,...e higher levels of inflammatory substances in the ...ight; as shown by a research project of the Univer...oto, a scientist at the School of Pharmacy. , Th...ic study in relation to the control of body weight...
(Date:11/23/2009)..., , Cambridge, Mass. November 23, 2009 Applie...lantain lily ( Hosta lancifolia ), a characteristi...closely packed ripples along the edges. The simple...ion resulting from bending during differential gro...ue, stretching foam ribbons. , Haiyi Liang, a po...
(Date:11/23/2009)..., IRVINE, Calif. -- More than 160 participants ga...cademies Keck FUTURES INITIATIVE conference. This ...r scientists, engineers, and medical researchers t...issues surrounding the emerging field of synthetic...cular biology at Princeton University and this yea...
Breaking Biology News(10 mins):It can be predicted the reaction obese patients will have to a diet 2The cause behind the characteristic shape of a long leaf revealed 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2University of Texas Picosatellite to be launched from space shuttle to begin milestone mission 12548 1University of Texas Picosatellite to be launched from space shuttle to begin milestone mission 12548 2University of Texas Picosatellite to be launched from space shuttle to begin milestone mission 12548 3Data Demonstrated ACTEMRA 28R 29 28tocilizumab 29 Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 4577 1Data Demonstrated ACTEMRA 28R 29 28tocilizumab 29 Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 4577 2Data Demonstrated ACTEMRA 28R 29 28tocilizumab 29 Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 4577 3Data Demonstrated ACTEMRA 28R 29 28tocilizumab 29 Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 4577 4Data Demonstrated ACTEMRA 28R 29 28tocilizumab 29 Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 4577 5Data Demonstrated ACTEMRA 28R 29 28tocilizumab 29 Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 4577 6Data Demonstrated ACTEMRA 28R 29 28tocilizumab 29 Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 4577 7Data Demonstrated ACTEMRA 28R 29 28tocilizumab 29 Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients 4577 8Fast pandemic detection tool ready to fight flu 48386 1Fast pandemic detection tool ready to fight flu 48386 2Fast pandemic detection tool ready to fight flu 48386 3
...on "traditions" to other members of their group, a...our. The findings add to evidence that cultural le...nvolved killerwhales at Marineland in Niagara Fall...brand new way to catch birds, and passed the strat...s gulls into his tank by spitting regurgitated fis...
...of Standards and Technology (NIST), in support of ...search Network (EDRN), has validated the measureme...al DNA as an early indicator for certain types of ...ly simple diagnostic test using a DNA microarray "...umors, including lung cancer. , Mitochondrial DNA ...
...neath the living brain,s surfaceResearchers at Sta...nimally invasive optical technique that can captur...ive subjects. The method, called two-photon microe...mechanical techniques into one device that fits in...eptember 1, 2005 issue of Optics Letters, a journa...
Other Biology News:More animals join the learning circle 2Microscopic brain imaging in the palm of your hand 2Microscopic brain imaging in the palm of your hand 3
Rabbit Anti-HES1 Antibody, Unconjugated from ABR-Affinity BioReagents
Rat Anti-Mouse Endoglin Monoclonal Antibody, Fluorescein Conjugated, Clone 209701 from R&D Systems
Caspase Inhibitor Ac-DEVD-CHO, Unconjugated from Promega
Coriolis equipment from Bertin Technologies
Biology Products: